Drugs / ATB-346
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03220633 | Jun → Dec 2014 | chronic pain syndrome | Antibe Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03291418 | Sep 2017 → Mar 2018 | gastric ulcer | Antibe Therapeutics Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03978208 Comparator | Mar → Dec 2019 | osteoarthritis | Antibe Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATB-346 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03291418 ↗ |
| Modality | Small molecule | — CHEMBL4211107 ↗ |
| Route | Oral | “orally administered” NCT03220633 ↗ |